BMS Gains Expanded Territorial Rights to Anti-PD-1 Antibody from Ono Pharmaceutical
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 10 (Table of Contents)
Published: 3 Oct-2011
DOI: 10.3833/pdr.v2011.i10.1565 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In exchange for Japanese co-development and co-commercialisation rights to its rheumatoid arthritis biologic Orencia® (abatacept), Bristol-Myers Squibb (BMS) has gained expanded territorial rights from Ono Pharmaceutical to BMS-936558/ONO-4538, an anti-programmed cell death (PD-1) antibody in Phase I and II clinical trials in the US for a number of tumour types...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS